{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03187431",
      "OrgStudyIdInfo": {
        "OrgStudyId": "AssiutU4"
      },
      "Organization": {
        "OrgFullName": "Assiut University",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Role of Stem Cell Therapy in Interstitial Pulmonary Fibrosis",
      "OfficialTitle": "Mesenchymal Stem Cell as Therapeutic Modality in Interstitial Pulmonary Fibrosis"
    },
    "StatusModule": {
      "StatusVerifiedDate": "June 2017",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Not yet recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "December 11, 2017",
        "StartDateType": "Anticipated"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "October 1, 2018",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 1, 2018",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "April 11, 2017",
      "StudyFirstSubmitQCDate": "June 13, 2017",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "June 15, 2017",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "June 13, 2017",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "June 15, 2017",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Aliae AR Mohamed Hussein",
        "ResponsiblePartyInvestigatorTitle": "Prof. Dr. Aliae AR Mohamed-Hussein, Professor of Pulmonology",
        "ResponsiblePartyInvestigatorAffiliation": "Assiut University"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Assiut University",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "Currently, the application status of MSCs as treatment modalities in IPF is still in its infancy and remains exploratory. Although a number of safety and efficacy clinical trials of MSCs as therapeutic options in immune-mediated and cardiac diseases have already been published with tantalizing results, to our disappointment, pulmonary and critical care medicine have traditionally lagged behind other therapeutic and research fields including hematology, gastroenterology and cardiology in translational studies of the use of reparative cells"
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Stem Cell Transplant Complications"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Stem cell",
          "Therapy",
          "IPF"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "12",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "IPF patients",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "autologous bone marrow mesenchymal stem cells",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: autologous bone marrow mesenchymal stem cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "autologous bone marrow mesenchymal stem cells",
            "InterventionDescription": "intravenous infusion",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "IPF patients"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "number of participants with treatment related side effects as infection, allergic reaction, disease acute exacerbation, and ectopic tissue formation",
            "PrimaryOutcomeDescription": "safety and side effects",
            "PrimaryOutcomeTimeFrame": "6 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Post therapy diffusing capacity of CO% (DLCO)predicted",
            "SecondaryOutcomeDescription": "Efficacy of procedure",
            "SecondaryOutcomeTimeFrame": "6-12 months"
          },
          {
            "SecondaryOutcomeMeasure": "post therapy forced vital capacity (FVC)% predicted.",
            "SecondaryOutcomeDescription": "efficacy of the procedure",
            "SecondaryOutcomeTimeFrame": "6-12 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nAge 18 to 75 years (both inclusive)\nhigh-resolution computed tomography (HRCT) scan that is very suggestive or consistent with a probable diagnosis of usual interstitial pneumonia.\nBronchoalveolar lavage must be performed at any time before inclusion and must have failed to show features supporting alternative diagnoses.\nThe duration of the disease should be more than three months, and bibasilar inspiratory crackles should be present.\ndyspnea score of at least 2 on a scale of 0 (minimum) to 10 (maximum).\nFVC > 50% of the predicted normal value and DLco > 35% of the predicted value.\nPatients under treatment with n-acetylcysteine or pirfenidone should discontinue drug and enter a wash-out period for at least 6 weeks prior study enrolment.\n\nExclusion Criteria:\n\nFVC < 50% predicted normal value and DLCO < 35%predicted normal value.\nlung cancer or with an evidence of active malignancyfor at least 5 years.\nuncontrolled heart failure.\nrenal failure\nhepatic failure,\nneurological abnormalities including stroke and myasthenia Gravis\nAnti-coagulants therapy.\nActive infections.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "65 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000011658",
            "ConditionMeshTerm": "Pulmonary Fibrosis"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000008171",
            "ConditionAncestorTerm": "Lung Diseases"
          },
          {
            "ConditionAncestorId": "D000012140",
            "ConditionAncestorTerm": "Respiratory Tract Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M7637",
            "ConditionBrowseLeafName": "Fibrosis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M13664",
            "ConditionBrowseLeafName": "Pulmonary Fibrosis",
            "ConditionBrowseLeafAsFound": "Pulmonary Fibrosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10320",
            "ConditionBrowseLeafName": "Lung Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14129",
            "ConditionBrowseLeafName": "Respiratory Tract Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC08",
            "ConditionBrowseBranchName": "Respiratory Tract (Lung and Bronchial) Diseases"
          }
        ]
      }
    }
  }
}